Prana Biotechnology Commences Phase I Clinical Trial of PBT2

Prana Biotechnology has commenced the Phase I clinical trial of PBT2 with the dosing of its first subject at a facility associated with the Utrecht University Hospital in Utrecht, Netherlands.

The Phase I clinical trial is the first of a planned series of studies examining the safety and pharmacokinetics of PBT2 in normal human volunteers. PBT2 is the first completely Prana-discovered compound, and is the successor to PBT1 for the treatment of Alzheimer's disease.

PBT2 is designed to have an improved safety and efficacy profile compared to PBT1. The compound has demonstrated significantly greater effectiveness in lowering plaque in the transgenic mouse model in both preclinical in-vitro and in-vivo testing. Moreover, it appears to be better than PBT1 at decreasing the toxicity of plaques through improved peroxide inhibition, and appears to have better pharmaceutical characteristics, such as improved solubility.